Pembrolizumab,Vibostolimab,Gebasaxturev,MK-4830,Favezelimab
Merck
[]
#aacr23 abstracts to be released today at 12 est. see all the companies presenting on our conference calendar: refer to our aacr article for more info on upcoming catalysts: and set your notifications for aacr press releases 
FDA catalyst calendar, newsletters, and more. We do not provide investment advice or recommendations. #biotech #stocks